Adaptive Biotechnologies (ADPT) Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Revenue across 9 years of filings, most recently posting $70.9 million for Q1 2026.

• Revenue for Q1 2026 came in at $70.9 million, up 35.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $295.4 million (up 55.87% YoY), and the FY2025 annual result was $277.0 million, up 54.77% from the prior year.
• Revenue came in at $70.9 million for Q1 2026 at Adaptive Biotechnologies, down from $71.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $94.0 million in Q3 2025 to a low of $7.7 million in Q2 2023.
• The 5-year median for Revenue is $46.4 million (2024), against an average of $49.5 million.
• Across the five-year window, Revenue slumped 82.36% in 2023 and soared 460.91% in 2024, its largest moves.
• Adaptive Biotechnologies' Revenue stood at $55.2 million in 2022, then retreated by 17.05% to $45.8 million in 2023, then rose by 3.66% to $47.5 million in 2024, then surged by 51.04% to $71.7 million in 2025, then slipped by 1.13% to $70.9 million in 2026.
• The last three Revenue figures came in at $70.9 million (Q1 2026), $71.7 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.